A director acquired 17,500 PBLS shares at $27.06, increasing indirect holdings to 30,000 shares after the company’s recent IPO.
A director of Parabilis Medicines (NASDAQ:PBLS) bought 17,500 shares in open-market transactions for approximately $474,000, according to an SEC filing. The purchases occurred on June 12 and June 15, 2026, at a weighted average price of $27.06 per share.
The transaction increased the director’s indirect holdings, held via Apothecary Capital LLC, to 30,000 shares. The purchase price was 8.2% above the June 15, 2026, market close of $25.85. Direct holdings remained unchanged at zero.
The filing noted the transaction represents the largest single reported addition to the director’s indirect holdings, following limited prior activity.